PSA tests might hurt a lot more than you think

By Theodore Cohen:On Wednesday, May 16, Dendreon Corporation (DNDN) announced four presentations to be given at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, taking place June 1-5, 2012 in Chicago, Illinois. These are:

By Bryce Istvan:Prostate cancer, the second most common cancer diagnosed in men, stole the drug headlines last week. Over two million men in the U.S. are currently living with prostate cancer. In 2011 there will be an estimated 240,000 new cases diagnosed and almost 34,000 people will die from it, according to the American Cancer Society. With this large a market it is no wonder that numerous companies are targeting the disease. There are currently about 30 prostate cancer drugs in clinical trials

By Robert Freedland: There has been a great deal of discussion about the news of Warren Buffett and his Stage I Prostate cancer revelation.

By Amy Baldwin:Genomic Health, Inc.'s (GHDX) stock has risen over 31% in the last month.

Some of the tests are aimed at reducing false alarms. Others probe the genetic workings of the cancer to distinguish dangerous tumors from slow-growing ones.

This is a great op-ed by Richard Ablin, discoverer of the prostate-specific antigen test, about the misuse to which his discovery has been put:

Tycoon Warren Buffett announced Tuesday that he has early-stage prostate cancer, and indicated he had no intention of stepping down as head of his investment firm Berkshire Hathaway.Buffett, in a letter to Berkshire shareholders, said he had been diagnosed with Stage I prostate cancer last Wednesday and would undergo radiation treatment beginning in mid-July.Imaging tests revealed no cancer elsewhere in his body, he said.